Key Points:
-
- In vivo delivery of a CD3-directed lentivector that encodes a CD19 CAR leads to the generation of CAR+ cells with a T and NK (TaNK)-like phenotype
- The newly generated CAR-TaNK cells are capable of eliminating CD19 B cells in a dose dependent manner, relative to the amount of lentivector delivered.
- Mice injected with the lentivector also displayed reduced levels of inflammation in the liver and colon, suggesting possible application in autoimmune indications
- The GCAR in vivo lentivector delivery platform represents a promising platform that can lead towards a true off-the-shelf CAR-T therapy
